Adalimumab biosimilar (PlantPraxis)

阿达木单抗生物类似药（PlantPraxis）

Report date: 2025/05/06 15:48:48

Base Information

Drug NameAdalimumab biosimilar (PlantPraxis)
Drug Alias NameAMAB
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsInflammationArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBrazil
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPharmaPraxisPlantForm Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPharmaPraxis
Active IndicationsN/A
Inactive IndicationsInflammationArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A